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ABSTRACT
Anthracyclines remain widely prescribed and successful anticancer agents, despite
serious side effects. Doxorubicin (DOX) is the most prominent anthracycline used to treat
many cancers, including hematologic malignancies, soft-tissue sarcomas, cancers of the
head and neck, and breast cancer. However, the clinical application of DOX is limited by
the development of life-threatening cardiomyopathy and congestive heart failure. The main
mechanisms of cardiotoxicity are thought to be mediated through the C-13 carbonyl and
quinone ring structures in DOX. To improve the anticancer activity and reduce the
cardiotoxic side effects of DOX, two synthetic analogs (GPX-150 and GPX-160) were
developed and tested for in vitro and in vivo activity against a panel of soft tissue sarcoma
cells. The analogs were further subjected to an array of tests to examine drug stability,
transport properties, topoisomerase inhibitory activity and metabolism by cytochrome
P450 enzymes.
The two analogs were effective anticancer agents against an array of cancer cells. In
particular, GPX-160 exhibited in vitro cytotoxicity against human soft tissue sarcoma
(STS) cells that was similar to DOX. Importantly, GPX-160 functioned equally well
against both DOX-sensitive and DOX-resistant sarcoma cell lines, suggesting that its
structural modifications allowed it to resist P-glycoprotein mediated drug efflux.
Moreover, in a murine xenograft model of human STS, both GPX-150 and GPX-160
treatment resulted in significant decreases in both fibrosarcoma tumor volume and weight
relative to the vehicle-treated controls.
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The stability of the DOX analogs in tissue culture media suggest that in the absence of
drug metabolizing enzymes, GPX-150 (t1/2 = 55.9 hr) will persist approximately 8-fold
longer than DOX (t1/2 = 6.8 hr) and 3-fold longer than GPX-160 (t1/2 = 20.7 hr). In vitro
drug absorption studies across Caco-2 cell monolayers indicate that GPX-150 and GPX160 have higher permeability coefficients than DOX in both apical-to-basolateral and
basolateral-to-apical directions. However, the transport of the analogs is not as heavily
polarized in the basolateral-to-apical direction, as is seen with DOX. Both analogs also
inhibited human topoisomerase IIα at low micromolar concentrations, supporting the
possibility that they share a similar primary mechanism of action with DOX. Finally,
human liver microsome metabolism of the two analogs showed that they were insensitive
to aldo-keto reductase activity, which was expected based on the loss of the C-13 carbonyl
and quinone structures. However, GPX-150 and GPX-160 remained sensitive to CYP2C8
and CYP3A4 activity.
Overall, these studies serve as an initial characterization of two DOX analogs that
appear to hold great promise as a next generation of anthracyclines that overcome
problems of drug resistance, while mitigating the cardiotoxicity that has limited the use of
DOX.
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CHAPTER ONE: INTRODUCTION
1. Cancer
Cancer is marked by the uncontrolled proliferation of genetically damaged cells that do
not respond to the normal regulatory mechanisms employed in multicellular organisms.
The uncontrolled proliferation of cancer cells interferes with the nutrient uptake of adjacent
normal cells. With time, growing masses of cancer cells can crowd and outcompete healthy
cells for resources and compromise vital tissue functions.
Abnormal cells can become either benign or malignant tumors. Benign tumors are not
cancerous as they grow slowly, are limited to a specific location, and rarely cause death.
On the other hand, malignant tumors are eventually lethal as they undergo metastasis and
often spread through lymph vessels or the bloodstream to distant parts of the body.
Malignant tumors disrupt biological activities of normal cells, and if left untreated, can
lead to death.
Cancer is the second most common cause of death in the U.S, preceded only by heart
disease. An estimated 1.7 million new cancer cases are presumed to be diagnosed in 2017
and about 600,000 patients are expected to die of cancer1. Breast carcinomas and prostate
cancers are the most common cancers for females and males, respectively. Lung cancers
are the leading cause of death for both women and men.
Cancers are classified by the tissues affected. The majority of cancerous tumors are
carcinomas, in which tumors originated from epithelial tissue, such as skin, glands, and the
lining of most internal organs. Leukemias are cancers of the bone marrow where leukocytes
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are produced. Similarly, lymphomas are cancers in which lymphocytes uncontrollably
proliferate in the lymph nodes. Tumors originating in connective tissue are called
sarcomas. Compared to the other cancer types, sarcomas are understudied due to their low
rate of occurrence.
2. Soft Tissue Sarcomas
Soft tissue sarcomas (STS) are a rare type of cancer derived from transformed cells of
mesenchymal origin. STS represent 1% of all adult cancers and can originate in many types
of tissue including adipose tissue (liposarcoma), skeletal muscle (rhabdomyosarcoma),
smooth muscle (leiomyosarcoma), and blood and lymph nodes (angiosarcoma)2. The
identification of STS relies on clinical examination, imaging, and histologic analysis 3.
There are more than 50 subtypes of STS4. Most sarcomas occur in the extremities account
for 60-70% (about 40% lower and 20% upper) of STS3.
Surgery is the typical treatment for local control of extremity STS followed by radiation
and chemotherapy. The 5-year local control rates in patients with adjuvant radiotherapy
improved by 18% compared with those treated with surgery alone5. Adjuvant doxorubicinbased chemotherapy also improves overall survival for metastatic STS as it reduces the
risk of local recurrence by 27% with an absolute benefit of 6% at 10 years. Even though
systematic control by chemotherapy can be useful, the overall outcome of STS treatment
is unsatisfactory and survival rates have remained stagnant for more than 50 years6. In
addition, the use of adjuvant chemotherapy is limited and controversial. Doxorubicin, the
single most active chemotherapeutic agent for STS, shows a 30% overall response rate but
causes cardiotoxicity as a side effect, which limits its use6. Therefore, new
chemotherapeutic regimens are required for treatment of STS.
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3. History of Doxorubicin
Doxorubicin (DOX, Adriamycin®, 14-hydroxydaunorubicin, NSC-123,127) is one of
the anthracycline-based antitumor agents considered as a mainstay chemotherapeutic since
its approval for use in 19747. The parent compound of DOX is daunorubicin (DNR). DNR
was first isolated in the early 1960’s from pigment-releasing Streptomyces peucetius var.
caesius strains, followed by the discovery of DOX8. Early on, DNR was found to be potent
in treating leukemias and lymphomas9. Later, DOX was found to be a better anticancer
agent than DNR for treating a variety of cancers, including leukemias, Hodgkin’s and nonHodgkin’s lymphomas, and solid tumors of the breast, lung, ovaries, bladder, thyroid, and
stomach10. DOX was also found to be effective in the treatment of multiple myeloma and
STS, including Kaposi’s sarcoma11.
Since the 1960s, hundreds of DOX analogs have been synthesized and investigated for
anticancer activity12, although few have progressed to common clinical use. Despite the
potential for significant adverse effects, DOX remains one of the most prescribed
chemotherapeutic agents. It is considered by the World Health Organization to be so
important that it is on their “List of Essential Medicines” that should be available in a health
care system13.
4.

Structures of Doxorubicin and Early Analogs

Structurally, anthracyclines consist of a daunosamine sugar moiety linked to a
tetracycline with neighboring quinone and hydroquinone groups in the center, a methoxy
group at C-4, and a short side chain with a carbonyl group at C-13 (see Figure 1). The
daunosamine sugar is composed of a 3-amino-2, 3, 6-trideoxy-L-fucosyl substituent, and
is attached at C-7 of the tetracyclic ring. The differences between DNR and DOX exist at
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the short side chain next to the C-13 carbonyl group attached to the A ring. DNR contains
a methyl group that is hydroxylated in DOX. Idarubicin (IDA, 4-demethoxydaunorubicin)
and epirubicin (EPI, 4’-epidoxorubicin) are first generation anthracycline derivatives of
DNR and DOX, respectively. IDA represents DNR without a C-4 methoxy group on ring
D. EPI resembles DOX, but has an axial-to-equatorial epimerization of hydroxyl group in
the sugar moiety, thus forming an acosamine instead of daunosamine sugar. Due to the
very similar structures, these compounds share similar mechanisms of action for their
antitumor effects.

Figure 1.1

Structures of early anthracyclines

5 Mechanisms of Action of Doxorubicin
The antitumor activity of DOX has been investigated for several decades since its
discovery. The three most widely accepted mechanisms of action are as follows: (1) DNA
intercalation and inhibition of topoisomerase activity14, (2) production of reactive oxygen
and nitrogen species (RONS) yielding DNA damage and/or lipid peroxidation15, (3) and
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formation of DNA adducts and/or crosslinking to proteins to interrupt replication and
transcription16.
5.1 DNA Intercalation and Topoisomerase II Poisons
DOX initially intercalates between DNA base pairs to form a stable DOX-DNAtopoisomerase II, ternary complex. As a result, both DNA strands are cut but not resealed,
ultimately leading to extensive DNA damage. The structure of DOX explains how it
intercalates DNA and forms this stable complex. For instance, the planar ring system of
DOX drives DNA intercalation through numerous hydrophobic interactions as the B and
C ring overlaps adjacent base pairs, and the D ring passes through the intercalation site (see
Figure 2). The non-intercalating groups such as the sugar moiety and ring A, stabilize the
cleavable complex17. The sugar moiety associates with the minor groove of DNA and
topoisomerase complex to deform the DNA structure18,19. It has been demonstrated that the
removal or modification of amino- substituents at the C-3’ position in the sugar and/or
methoxy group at C-4 in the D ring increases the topoisomerase II (Top2) poisoning,
thereby increasing the overall anticancer activity20–22.
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A
B
C
D

Figure 1.2. Stereoscopic skeletal sketch of the DOX-DNA complexes (left) and
stacking interaction between DOX and the adjacent base pairs in a perpendicular
view (right). DOX (dark bonds) intercalates between the terminal two base pairs
of DNA as the sugar moiety penetrates through the helix. The sugar residue and
ring A reside outside of the intercalation site and stabilize the ternary complex.
The N-3 amino group of the sugar lies in the minor groove, and can also form a
covalent bond with the guanine base of DNA (modified from Zhang et al., 1993).

Several studies have classified DOX as a Top2 poison23,24. DNA topoisomerases are
ubiquitous enzymes that play a crucial role in regulating genomic integrity. These enzymes
supervise the topology of cellular DNA by catalyzing the unwinding of DNA supercoiling
through DNA strand passage and re-ligation without altering its sequence and structure.
Topoisomerases regulate DNA replication, recombination, repair, transcription, and
apoptotic DNA degradation25. Topoisomerases are divided into two subfamilies based on
their chemical structure: topoisomerase I (type 1) and II (type 2). Topoisomerase I is a
monomer, which transiently cleaves a single-strand of DNA duplex to unwind the
supercoiled-DNA. In contrast, topoisomerase II is an oligomer that transiently cleaves both
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strands of the DNA duplex, relaxing the supercoiled-DNA26. Six different topoisomerases
exist in human cells: 1A (Top3α and β), 1B (Top1 and Top1mt), and 2a (Top2α and β)27.
Top2α is a nuclear isozyme composed of a dimer of two identical subunits that requires
ATP hydrolysis (Figure 3)28. The enzyme appears in fast-growing cancer cells, and is a
primary molecular target for DOX29. DOX interaction with Top2-DNA covalent
complexes induces DNA damage, including double-strand breaks (DSBs). DSBs in
chromosomal DNA induced by DOX are stabilized by the proteosome31,32. In response to
DSBs, the histone H2A variant γ-H2AX is phosphorylated and initiates a signaling cascade
that alerts the cell to DNA damage, leading to growth arrest in G1 and G2 phases, and
apoptosis33,34.
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DOX
II
II
DOX
I

DOX
IV

DOX
III
III
DOX inhibits topoisomerase II (Top2) at several sites in the reaction

Figure 1.3.
cycle: I. DOX can block Top2 binding to the G segment of DNA (blue). II. DOX can
also inhibit the advancement of the DNA T segment (red) into the central hole before
ATP binds to the ATPase domain (yellow). III. DOX interferes with release of the
T segment from the A and A’ domains (green) at the bottom of the dimer. IV. DOX
interrupts ATP hydrolysis and regeneration of the starting state (modified from
Nitiss, 2009).
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5.2 Production of Free Radicals and Reactive Oxygen Species (ROS)
The quinone moiety in ring C of DOX can undergo a one-electron reduction catalyzed
by flavin oxido reductases35, forming a semiquinone that decomposes to the parent
quinone and reduces oxygen to reactive species such as hydrogen peroxide (H2O2),
superoxide anion (·O2-)36, and ultimately hydroxyl radical (·OH) (Figure 4). In a
biological environment, ·OH can interact with cellular constituents, creating adducts
of cellular DNA, peroxidizing lipids, or oxidizing tryptophan-, tyrosine-, and thiol-

-

1 e reduction

Oxido-reductases

+ O2

•

-

O2

H2O2
•

+ Fe II/III

OH

Intracellular
oxidative damage

Figure 1.4. The production of reactive oxygen species (ROS) and free
radicals from doxorubicin by one-electron reduction catalyzed by oxidoreductases.
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containing functional groups in proteins and enzymes. Ultimately, these events
disrupt function and lead to cell death37.
DOX decomposition can create RONS through other routes as well. Reductive
deglycosylation of DOX to a 7-deoxyaglycone is generated during the one-electron
reduction cycle as the semiquinone may also oxidize the bond between the A ring and sugar
moiety38. These aglycone products can readily permeate cells and organelles because of
their increased lipid solubility to produce intracellular RONS39. RONS can also oxidize
signaling molecules that modulate the activity of kinases or transcription factors, disrupting
the cell cycle and stimulating apoptosis40–43.
Free radical generation can also be mediated by metals, particularly iron. DOX forms
an iron coordination complex with dinucleotides44,45. Several studies have shown that the
presence of the C-11 hydroxyl group is fundamental for iron binding and thiol-dependent
oxygen consumption. DOX can complex with iron to directly reduce Fe (III) to Fe (II),
which then reacts with molecular oxygen or hydrogen peroxide to sponsor DNA adduct
formation46. This iron-DOX complex mediates oxidative damage and is considered one of
the primary mechanisms of DOX anticancer action.
5.3 DNA Adducts and Cross-linking
In addition to creating DOX-DNA-Top2 complexes that disrupt DNA replication
through stabilized double strand breaks, DOX can also directly form covalent DNA adducts
that lead to cytostatic effects47,48. These direct DNA-adducts were first described by Sinha
and Chignell in 197949. Formaldehyde in the cell creates a methylene group at the 3’ amino
moiety on the sugar of DOX and binds to the N-2 residue of guanine in the DNA (Figure
5). This reactive intermediate attacks the 2-amino group of deoxyguanosine residues in the
DNA via Schiff base chemistry to create the DOX-DNA adduct16,50,51. Reaction rates can
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be increased through catalysis by xanthine oxidase and NADPH52. Cullinane and Philips
discovered that DOX can create adducts with both single and double stranded DNA and
hypothesized that this occurred through a quinone methide intermediate12. Taatjes and
Koch et al. suggested that DOX iron-catalyzed free radical reactions induce formaldehyde
production from cellular carbon sources such as lipids and spermine in an oxidative stress
environment, thus stimulating DOX-DNA adduct formation53,54.
3’

3

5’

’
D

C

B

A

1
2

1
2
5’

3’

Figure 1.5. Structure of doxorubicin showing its covalent and noncovalent bonding position to the c- and n-strands of DNA. Rings B, C, and
D can intercalate in the minor groove of DNA. DNA-adducts are mediated
through N-2 guanine nucleoside (blue) of DNA in either strand. The noncovalent strand form hydrogen bonds with the hydroxyl group at ring A of
DOX. The covalent linkage between the amino group of DOX and c-strand
guanine N-2 derives from direct reaction with formaldehyde. The aminal
(N-C-N) bond between N-3 amino group of guanine and daunosamine sugar
forms DNA covalent cross linkages at 5’-GC-3’ sites.
DNA cross-linkage is proposed to occur in a series of steps. Step 1 involves the
interaction of DOX with the binding site of DNA, which yields the drug-DNA complex.
In step 2, formaldehyde released from carbon sources via iron-catalyzed free radical
reactions interacts to generate a covalent complex between the amine group on the DOX
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sugar and the N-2 amine group on the guanine base of the c-strand. Meanwhile, the N-3
amine group in the guanine base of the DNA n-strand hydrogen bonds with the hydroxy
group on ring A of DOX. Lastly, in step 3, formaldehyde produces the cross-linked ternary
complex55. This primarily occurs between the daunosamine sugar and the N-2 amino group
of guanine via an aminal (N-C-N) bond49,55,56, predominantly cross-linking at 5’-GC-3’
sites in DNA12.
The concentration of formaldehyde is often higher in cancer cells than in normal cells57,
thus DOX-DNA cross-linkage occurs more readily in cancer cells. As well, novel DOX
analogs that more readily conjugate to formaldehyde should produce significantly
enhanced rates of DNA adducts. A number of these analogs have been developed such as
doxazolidine, doxoform, and doxaliform. DNA-drug adducts formed by these compounds
and formaldehyde exhibited increased cytotoxicity in comparison to DOX, and they were
less susceptible to drug-efflux based drug resistance58,59. The structure of DNA adducts is
well supported by mass spectrometry16,50, 2D NMR51, and X-ray crystallography60.
6. Mechanisms of Cardiotoxicity
Although DOX is one of the most successful chemotherapeutic compounds, its clinical
use is restricted by selective myocardial dysfunction, and dose-dependent reversible and
irreversible cardiotoxicity60,61,62,63,64. This can result in pericarditis, arrhythmias, and left
ventricular dysfunction65,66. The decreased left ventricular ejection fraction (LVEF)
eventually leads to congestive heart failure (CHF)67. A decrease in LVEF and
asymptomatic abnormalities may occur in patients at cumulative doses of DOX as low as
300 mg/m2. The characterization of dose-induced cardiomyopathy is seen as a flattening
of the T-wave, increased Q-T interval, reduced R-wave amplitude, atrial flutter, and
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premature atrial and ventricular beats68,69. LVEF dysfunction results in a decrease in both
systolic and diastolic function, with a substantial increase in left ventricular end-diastolic
pressure70. At cumulative doses of 240 mg/m2 of DOX, significant histopathologic changes
can also be seen in endomyocardial biopsy specimens, including loss of myofibrils,
alteration to the sarcoplasmic reticulum, and increased vacuoles in the cytoplasm
18,34,40,54,55,58,59

.

Cardiotoxicity can be categorized into three distinctive types: acute/subacute, early,
and late-onset chronic progressive cardiotoxicity. Acute/subacute cardiotoxicity occurs
within a week of DOX treatment, and explains observed transient arrhythmias72,73,74,75. In
contrast, both early- and late-onset cardiotoxicity are categorized by a dose-induced,
progressive reduction in LVEF with either symptomatic or asymptomatic cardiac
abnormalities76,77. Early-onset cardiotoxicity occurs within a year of treatment, while lateonset chronic cardiotoxicity may develop between 4 and 15 years after treatment has
ended.78
A number of investigations have studied the pathophysiology of DOX-induced
cardiomyopathy. However, the molecular mechanisms still remain debatable and are
incompletely understood. The main proposed mechanisms of cardiotoxicity are RONS
overproduction by single electron reduction reactions39,79–82, and the reduction of the DOX
C-13 carbonyl group to an alcohol to generate a toxic metabolite, doxorubicinol (DOXol)
(Figure 6)81-86.
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Figure 1.6. Doxorubicin-induced mechanisms of cardiotoxicity via 1
electron and 2 electron pathways. The 1 electron reduction pathway explains
the production of reactive oxygen and nitrogen species (RONS). The two
electrons reduction pathway leads to production of the secondary alcohol
metabolite, doxorubicinol (DOXol).
6.1 DOX-induced RONS Mediated Cardiotoxicity
ROS can be generated via two significant molecular mechanisms: an enzymatic
pathway triggered by several oxidoreductases via one-electron reduction, and an enzymefree pathway induced by anthracycline-iron complexes. In the first pathway,
oxidoreductases catalyze reduction of the quinone moiety of the central anthracycline ring
into a radical semiquinone. The semiquinone reduces oxygen to create superoxide anion
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and hydrogen peroxide, and regenerate the parent quinone. This pathway occurs in
mitochondria by NADPH dependent ubiquinone oxidoreductase39,79,87–92, in microsomes
via NADPH-cytochrome P450 or NADPH-cytochrome b5 reductases88,93,94, and in the
cytosol by xanthine dehydrogenase and nitric oxide synthases36,52,95–97.
On the other hand, increased RONS formation can also be induced by anthracyclineiron complexes. In the presence of oxygen, anthracycline binds to free Fe (III), becoming
a drug-metal coordination complex. The complex generates superoxide anion and H2O2 as
it alternates redox interaction between Fe (II) and Fe (III). DOX also associates with both
hemoglobin98 and myoglobin, those can interact with iron98–103 or copper104–106, to generate
metal complexes that can form free radical species by spontaneous oxidation in solution.
The presence and amount of the respective oxidoreductases in specific cell types determine
the source and amount of free radical formation, and where it occurs within the cell69.
DOX-stimulated RONS production in cardiomyocytes causes mitochondrial damage
that leads to apoptotic cell death through activation of caspase pathways107–109. The
aglyconic form of DOX can also intercalate into mitochondrial membranes due to its high
lipophilicity, and create even more RONS as it directs more electrons towards oxygen in
single electron transfer reactions. In addition, DOX can generate peroxynitrite (ONOO-) as
a result of excess production of superoxide anion and nitric oxide (NO) from
overexpression of the inducible isoform of NO synthase (iNOS)110–113. Eventually, ONOOcan cause lipid peroxidation, protein nitrosylation, DNA strand breaks, and damage to a
variety of cellular macromolecules. Overall, this futile oxidative and nitrosative stress lead
cardiac dysfunction, mitochondrial damage69,114–118, energy imbalance116,119, and
apoptosis17,108,120.
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Cardiomyoctes are acutely susceptible to RONS, since they lack sufficient levels of
detoxifying enzymes such as superoxide dismutase, catalase, and gluthathione peroxidase,
to respond to the added oxidative stress elicited by DOX treatment121–123. The high
metabolic activity in heart tissue also causes cardiac failure124. Additionally, DOX
inactivates RONS detoxifying enzymes, thus increasing the likelihood of anthracyclineinduced cardiomyopathy.122,125
6.2 DOX-induced Doxorubicinol Mediated Cardiotoxicity
Doxorubicinol (DOXol) is a major metabolite of DOX that accumulates in
cardiomyocytes, where it is produced by mitochondrial aldo-keto reductases (AKR) that
reduce the C-13 carbonyl group to a secondary C-13 alcohol83. DOXol contributes to the
delocalization and swelling of mitochondrial matrix of cardiomyocytes126,127,128. DOXol
causes significant disruption to mitochondrial metabolism leading to declines in
myocardial ATP, lactate, and phosphocreatine concentrations. Ultimately, this disrupts
both oxidative and glycolytic metabolic pathways, causing severe cardiomyopathy129,130.
DOXol seems more effective than DOX at blocking the Ca2+-Mg2+ ATPase of
sarcoplasmic reticulum, the F0-F1 proton pump of mitochondria, and the Na+-K+ ATPase
and Na+-Ca2+ exchangers of the sarcolemma131. DOXol is also better than DOX at
inhibiting spontaneous or caffeine-triggered Ca2+-release from the sarcoplasmic
reticulum132. In vivo studies in rabbits suggest DOXol induces LVEF dysfunction and
interruption of the ryanodine receptor associated with the Ca2+ release channel of the
sarcoplasmic reticulum, whereas less LVEF shortening was found with treatment using C13 deoxy-DOX133. DOXol also modifies the aconitase/IRP-1 complex to a “null protein”
that is devoid of aconitase and RNA binding activity by causing oxidative damage to
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cysteine residues required to reconfigure an essential Fe-S cluster134–136. The inactivated
aconitase/IRP-1 complex is incapable of sensing iron and fails to trigger iron uptake or
sequestration, which consequence inactivates regulatory and metabolic pathways in the
cardiomyocyte15. Ultimately this imbalance in iron homeostasis negatively impacts the
heart systolic/diastolic cycle86.
7. Prevention of Cardiotoxicity
The effective use of DOX as an antineoplastic agent relies on the tissue concentration
of drug and/or the total systemic exposure over time, rather than the peak plasma
concentration146. Thus some of the problems encountered with acute or early DOX-induced
cardiotoxicity can be avoided by altering the schedule of administration. Instead of a single
bolus of drug by intravenous (IV) injection every 3 weeks, IV delivery of DOX over a
period of 48-96 hours and lower weekly doses have been shown to reduce CHF rates46,147–
150

. Regular monitoring for any clinical signs of cardiotoxicity by physical examination, x-

rays, echocardiogram, electrocardiogram (EKG), endomyocardial biopsy, and radionuclide
angiography before, during, and after DOX chemotherapy is necessary to avoid severe
CHF and morbidity. Physical examination by itself can detect more than 50% of early and
reversible DOX-dependent CHF.152–154
8.

Anthracycline Analogs

The cardiotoxicity encountered with DOX is inherent to its chemical structure. For
decades, DOX analogs have been explored to reduce the required drug dose to achieve a
therapeutic response, and to reduce cardiotoxic side effects and drug resistance. Some of
these DOX analogs are discussed below.
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8.1 Epirubicin
Epirubicin (4’-epidoxorubicin, EPI) is
synthesized from DOX by epimerization of a
hydroxyl group in the daunosamine sugar
(Figure 7). This minor positional change
discriminates

the

physicochemical

and

pharmacokinetic properties of EPI from DOX.

Figure 1.7. The structure of
epirubicin.

EPI is more lipophilic, has weaker base characteristics, and a shorter half-life than
DOX137,138. The rapid overall body clearance of EPI is due to β-glucuronidation by liver
UDP-glucuronosyl transferase 2B7139, which diminishes its overall dose-induced
cardiotoxicity140. EPI also undergoes limited one-electron reduction that predominantly
occurs in cytoplasmic acid organelles, rather than the mitochondria141. Like DOX, AKR
converts EPI to epirubicinol (EPIol) by limited two-electron reduction67,142,143. Several
clinical studies have shown that EPI treatment does not produce as much of the toxic
secondary alcohol in cardiac tissue149,150. CHF is not encountered with EPI at a single-dose
level of 900-1000 mg/m2, which is 1.5 times higher than the dose limit for DOX141,144. In
a study of breast cancer patients co-treated with 5-fluorouracil, cyclophosphamide, and EPI
(90 mg/m2), followed by radiation therapy, patients did not show sign of symptomatic CHF
in the first year of treatment145. Moreover, EPI-taxane combination therapy allowed a
cumulative dose of EPI that was almost twice as high as that recommended for DOX146.
However, minor LVEF was identified following cumulative EPI doses of 360-450 mg/m2.
EPI is still reduced to EPIol and the minor formation of RONS can harm cardiomyocytes
and decrease cardiac function147.
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8.2 Idarubicin
Idarubicin

(4-demethoxydaunorubicin,

IDA) is a DNR derivative that lacks a
methoxy group at position 4 (Figure 8). Like
DOX and other anthracyclines, IDA is a DNA
intercalating
topoisomerase

agent
II

that

function

interrupts
and

DNA

Figure 1.8. The structure of
idarubicin.

replication14. IDA has a higher lipophilicity than DNR, which results in an improved rate
of cellular uptake21, a longer half-life, and increased ability to cross the blood-brain
barrier148. IDA is another key component of chemotherapy regimens, and is potentially
superior to DNR in treatment of acute myeloid leukemia (AML)149,150 and acute
lymphocytic leukemia (ALL)151. Whereas DNR and DOX must be administered IV, IDA
shows good oral bioavailability, although no benefit between oral and IV administration
was observed for acute leukemia patients22. In randomized treatment trials, IDA showed
less cardiotoxicity than DNR152. The increased drug effectiveness and prolonged survival
in AML treatment makes IDA a better therapeutic than the parent DNR compound.
However, in AML patients receiving a cumulative dose of 290 mg/m2, decreased LVEF
and cardiomyopathy was observed21. Lastly, although IDA shows great potency in
leukemia treatment, it appears to be less effective than DOX in treatment of metastatic
breast cancer, and it still induces dose-dependent cardiotoxicity to those patients.153,154
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8.3 Dissaccharide Anthracyclines
A third generation of anthracycline analogs,
Sabarubicin

(MEN-10755)

and

morpholinyl-

derivatives such as nemorubicin (PNU-152243A), are
now being investigated to satisfy the need to have both
anticancer effectiveness and reduced dose-induced
cardiotoxicity (Figure 9). Both of these compounds are
designed to investigate the role of the C-3 amino group
of

the

daunosamine

sugar

to

disrupt

type-II

topoisomerase activity through DNA cleavage and
stabilization

of

the

drug-DNA-topoisomerase

complex.155-157
Sabarubicin is known to be a leading disaccharide

Figure 1.9. The
structures of sabarubicin
and nemorubicin.

analog that is reported to have a better antitumor efficacy than DOX. Structurally,
sabarubicin contains a 2,6-dideoxy-L-fucose between the algycone and sugar moieties with
an elimination of the methoxy substituent at C-4 in the aglycone. Sabarubicin exhibits an
increased spectrum of antiproliferative activity in human tumor xenografts158, improved
anti-topoisomerase II action159, and reduced cardiomyopathy when compared to DOX160.
The drug half-life of sabarubicin is 50% shorter than DOX and its cellular uptake and tissue
accumulation are slower161. Several in vivo studies report reduced conversion of
sabarubicin to its toxic secondary alcohol metabolite (sabarubicinol, MEN-10755ol), hence
lowering its cardiotoxic potential135,160. In addition, the alcohol metabolite of sabarubicin
is less reactive than DOXol toward the [Fe-S] cluster of cytoplasmic aconitase/IRP-1,
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which is involved in mediating anthracycline-induced cardiotoxicity162. In a phase I clinical
trial, sabarubicin still caused myelosuppresion, but the overall cumulative cardiotoxicity
was mild, and only two patients showed decreased LVEF163. Furthermore, a phase II study
of sabarubicin showed no CHF, although cardiotoxicity was observed in clinical trials in
patients with regionally advanced or metastatic platinum/taxane resistant ovarian cancer164.
Another disaccharide derivative that is being explored for clinical use is nemorubicin
(3’-deamino-3’ [2”-(S)-methoxy-4-morpholinyl] doxorubicin; MMDX), which is a DOX
derivative that retains a methoxymorpholinyl group at C-3 of the daunosamine sugar. Phase
I and II clinical trials show promising results for the intrahepatic artery delivery of MMDX
to treat hepatocellular carcinoma165–167. MMDX also shows encouraging efficacy against
multidrug-resistant tumor cells in vitro and in vivo168,169. While minor damage to cardiac
tissue was found by histological examination, in vivo studies of MMDX treatment at
optimal therapeutic doses did not result in abnormal EKG170. In both animal and human
clinical studies, MMDX appears to be 50-130 times more effective than DOX168,171.
However, MMDX is only 2-10 fold more potent than DOX against adenocarcinomas (i.e
ovarian and lung tumors) and hemocytoblasts in in vitro studies170,172. The increased antitumor activity may be due to the biotransformation of MMDX that leads to more cytotoxic
metabolites (MMDX N-oxide, PNU-159696, and PNU-159682)165,167.
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8.4 C-13 Deoxy Anthracyclines
Since the carbonyl group at C-13 and/or in the
quinone moiety has the notorious impact of causing
anthracycline-induced

cardiomyopathy,

novel

compounds lacking these structures have been
developed.

GPX-150

(5-imino

13-

deoxydoxorubicin; DIDOX) is one such compound.

Figure 1.10. The structure of
C-13 deoxy anthracycline,
GPX-150.

In GPX-150 the C-13 carbonyl has been removed,
and the quinone carbonyl has been replaced with nitrogen to generate an iminoquinone.
This structure is less capable of generating ROS and cardiotoxic alcohols (Figure 10).
Experimentally, GPX-150 is a poor substrate for carbonyl reductase173, likely due to the
absence of C-13 carbonyl group and quinone moiety. Holstein et al. demonstrated in a
phase I dose escalation study (as high as 265 mg/m2) that GPX-150 did not elicit acute
cardiomyopathy among patients with advanced solid tumors174. In fact, GPX-150 treatment
produced no clinically significant harm to cardiac function, even in patients with prior
anthracycline history and minor LVEF shortening174. Unlike other anthracyclines, GPX150 treatment does not cause common patient side effects such as mucositis, stomatitis, or
hand-foot syndrome. Further, a recent phase II study of GPX-150 for treatment of advanced
and/or metastatic malignant STS patients revealed that this novel analog was well tolerated
by patients with different sarcoma subtypes175. Furthermore, no irreversible cardiotoxicity
was found and the toxicity profile that did result from the drug treatment appears to be
manageable175.
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8.5 Cancer-Targeted Formulations
In an attempt to overcome the therapy-limiting toxicity of conventional anthracyclines
and to restrict anthracycline uptake into heart tissue, new pharmacological approaches have
been developed. One innovative approach is a liposomal formulation that shows promising
drug carrier technology to increase the therapeutic profile of DOX176,177. Liposomal
systems allow easy drug-delivery from the circulation into tumor tissue, in which cells are
not as tightly joined as cells in normal tissues202. However, the application of liposomeencapsulated DOX is limited due to its short half-life in plasma and the formation of
cardiotoxic metabolites179.
A number of liposomal DOX formulations that incorporate polymers such as
polyethylene glycol (PEG), ganglioside, and cerebroside sulfate have been shown to
actively target tumors and prolong serum half-life180. Pegylated-liposomal DOX (DOXil)
is an FDA-approved formulation that resists drug uptake by the reticuloendothelial system
(RES), improving its plasma half-life up to 4 days181. Also, DOXil remains encapsulated
until it has reached the tumor cells182,183. Despite the promising effects of DOXil, it can
still cause hand-foot syndrome (HFS or palmar-plantar erythrodyesthesia), which is
characterized by skin eruptions on the palms of the hands and soles of the feet184.
8.6 Cardioprotective Agents
Dexrazoxane (DZR, ICRF187, Cardioxane®) is the only drug
that has been approved in the U.S,
Canada, and Europe to protect
against

anthracycline-mediated

Figure 1.11. The structures of dexrazoxane
and its metal ion chelating hydrolysis product,
ADR-925.

24
cardiotoxicity185,186. DZR is a bisdioxopiperazine and an enantiomer of razoxane, which
was initially discovered as a chemotherapeutic agent. DZR quickly penetrates the cell
membrane and is enzymatically hydrolyzed to produce ADR-925, an active metal chelator
(Figure 11). ADR-925 ligates free iron and inhibits the generation of ROS by
anthracycline-Fe complexes. ADR-925 also readily dissociates Fe (III) from the
anthracycline-iron complexes. The cardioprotective mechanism of DZR is not fully
understood, but it is proposed to be a better chelator of Fe (III) than DOX, and thus blocks
iron-driven RONS production187. DZR also disrupts Top2 activity like DOX, although
through a distinct mechanism. DZR stabilizes the ATP-bound closed-clamp configuration
of Top2 through antagonist interaction with the Top2-DNA complexes188,189,190.
In the U.S, DZR is labeled as an orphan drug for treatment of metastatic breast cancer
in patients who have already received 300 mg/m2 DOX. The results of two Phase III clinical
studies reported that concomitant DZR treatment with fluorouracil, doxorubicin, and
cyclophosphamide (collectively referred to as “FAC”) in advanced breast cancer produced
significant cardioprotection191. Also, Swain et al. reported that DZR decreased cardiac risk
during DOX treatment 2.5-fold192. DZR is highly active in both adults and children, and
prevents DOX-induced oxidative damage to cardiomyocytes without interruption of DOX
anticancer activity193,194. Despite this, DZR use is limited due to severe exacerbation of
DOX mediated myelosuppression195.
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9. Conclusion
Studies to improve the clinical potency, efficacy, and safety of DOX and its analogs
are ongoing. DOX is the primary anticancer anthracycline in clinical use. It is hypothesized
that the mechanisms of DOX action as an anticancer agent include the fast diffusion into
the nucleus, where it intercalates between nucleotide base pairs of the DNA based on the
planar ring structure of the aglycone. Following intercalation, covalent adducts to the DNA
strand and DNA intrastrand cross-linkage are possible, as well as inhibition of
topoisomerase II activity that leads to DSBs and interruption of DNA replication.
Although DOX may be a useful chemotherapeutic due to its versatility in treating many
tumor types, it causes adverse effects in cancer patients. The main adverse effect of DOX
treatment is acute and chronic cardiotoxicity. This remains major problems to be resolved
in DOX therapy. The mechanisms by which DOX induces cardiotoxicity include
accumulation of reactive iron species (Fe2+ and Fe3+), formation of a toxic secondary
alcohol metabolite by carbonyl reductases, overproduction of hazardous RONS,
interference with calcium ion homeostasis, and mitochondrial dysfunction. Due to these
therapeutic problems with DOX, the design of second and third generation DOX analogs
to prevent cardiotoxicity and drug resistance, without losing the anticancer activity, has
progressed. The development of DOX disaccharides, C-13 deoxy anthracyclines,
liposomal formulations, and cardioprotective agents are new approaches to improve the
therapeutic profile of anticancer anthracyclines.
The goal of this study was to evaluate the ability of DOX derivatives to exert in vitro
cytotoxic effects against various human STS and normal cells, and reduce tumor growth in
an in vivo human STS xenograft model in nude mice. In addition, the ability of DOX
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analogs to overcome drug efflux mediated drug resistance, inhibit topoisomerase II, and
pharmacokinetics was characterized. The results indicate that the newest generation of
analogs are promising anticancer agents that should not stimulate cardiotoxicity and should
overcome drug resistance issues commonly encountered with DOX.
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CHAPTER TWO: IN VITRO AND IN VIVO ACTIVITY OF NOVEL DOXORUBICIN
ANALOGS AGAINST SOFT TISSUE SARCOMA

Abstract
Two novel synthetic analogs (GPX-150, GPX-160) of the anticancer agent doxorubicin
(DOX) were assessed for topoisomerase inhibitory activity and cytotoxicity against a panel
of human soft tissue sarcoma, breast carcinoma, and normal cell lines. In vitro cytotoxicity
experiments showed that GPX-160 generally exhibited sub-micromolar activity, with IC50
values against cancer cells that were similar to DOX. In contrast, GPX-150 was uniformly
less potent that either DOX or GPX-160. GPX-160 also retained equivalent submicromolar potency against both DOX-sensitive (MES-SA) and DOX-resistant (MESSA/MX2) cell lines, suggesting reduced susceptibility to efflux pump mediated drug
resistance found in the MES-SA/MX2 cell line. Finally, in an in vivo human xenograft
model of fibrosarcoma, mice treated with GPX-150 and GPX-160 showed significant
decreases in both tumor volume and tumor weight relative to control animals.
1. Introduction
Soft tissue sarcomas (STS) are a rare heterogeneous type of cancer that originate from
mesenchymal cells1. STS accounts for approximately 1% of all adult malignancies and 8%
of pediatric cancers2. While they can arise in any part of the body, STS more frequently
occur in the extremities (50% of patients) or in the trunk/retroperitoneal areas (40% of
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patients)1. More than 50 different histological types of STS are recognized by World Health
Organization (WHO)3. Disease severity and prognosis relies on several factors including
patient age and gender, tumor size, tumor spread, histological phenotype, and anatomical
location4,5.
STS treatment usually involves surgical resection of the primary tumor, followed by
radiation, and/or chemotherapy1. The primary chemotherapeutic used to treat STS is
doxorubicin (Adriamycin®), a water-soluble anthracycline first discovered in cultures of
Streptomyces peuceitus var. caesius in the 1960s after the discovery of daunorubicin
(DNR), its parent compound6,7. Doxorubicin (DOX) is a versatile chemotherapeutic that is
also used to treat a wide array of other cancers, including leukemias, lymphomas, and solid
tumors of the breast, ovaries, lungs and thyroid8,9. The primary mechanisms of anticancer
activity are mediated by intercalation into DNA and subsequent inhibition of
topoisomerase activity that ultimately interrupts DNA replication10.
Although DOX is one of the major prescribed anticancer drugs, its use is clinically
constrained due to well-known cardiotoxic side effects11. DOX treatment can cause both
acute and chronic dose-dependent cardiotoxicity, which eventually leads to congestive
heart failure. Acute cardiotoxicity can present itself within a week of a single dose of DOX
treatment12,13, while chronic cardiotoxicity may occur 4-15 years after the completion of
treatment14. The recommended cumulative dose of DOX is generally limited to less than
500 mg/m2 to reduce the increasing risk of heart failure that occurs beyond 550 mg/m2 13,1518

. Multiple mechanisms appear to be involved in DOX-induced cardiotoxicity, including

its reduction to toxic doxorubicinol (DOXol) by cytosolic NADPH-dependent aldo-keto
reductases (AKR1C3, AKR1A1, CBR1, CBR3)19-21, interruption of calcium and iron
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homeostasis, and generation of reactive oxygen and nitrogen species (RONS)22,23.
In order to improve the therapeutic profile of DOX, we analyzed synthetically modified
DOX derivatives, GPX-150 and GPX-160 (Figure 1). These novel analogs were designed
to reduce DOX-mediated cardiotoxicity by removing functional groups that promote
formation of the toxic DOXol metabolite and reactive oxygen and nitrogen species
(RONS), while retaining cytotoxicity against tumor cells. In the GPX-150 analog, the C13 carbonyl group was removed to prevent reduction to cardiotoxic DOXol. In addition, a
carbonyl oxygen in the quinone ring was replaced with a nitrogen to create an
iminoquinone with reduced capacity to stimulate formation of RONS24. The GPX-160
analog was further derived from GPX-150 by replacing the primary amine at the 3’ position
in the sugar moiety with a pyrrolino- group. This alteration in other analogs has been shown
to enhance the binding to the DNA-drug ternary complex25,26 and to reduce the
susceptibility to P-glycoprotein (P-gp) mediated drug efflux that is a common mechanism
of drug resistance in tumor cells27.
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Figure 2.1.
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The structures of DOX, GPX-150, and GPX-160.

In this report, we evaluate the in vitro inhibitory activity of the DOX analogs against
topoisomerase II α (Top2α), since this is a primary target of anthracycline action. The in
vitro cytoxicity of the compounds against a panel of STS, carcinoma, and normal cells were
also determined to investigate how alterations to chemical structure influence their
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anticancer profile. Finally, we report the comparative activity of DOX, GPX-150, and
GPX-160 analogs in an in vivo murine xenograft model of human fibrosarcoma. The result
demonstrates the efficacy of these analogs at reducing tumor growth and suggest their
usefulness as novel anticancer agents.
2. Results/Discussion
2.1

A

Inhibition of Topoisomerase IIα
DOX is a DNA intercalating agent that
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Figure 2.2
Topoisomerase inhibitory
activity. [A] Representative agarose gel of
Top2α-kDNA decatenation reaction
products. High molecular weight catenated
kDNA, low molecular weight linear kDNA
and decatenated circular kDNA standards
are seen in the first three lanes. The
remaining lanes show Top2α reactions
containing 0–20 μM of GPX-160. [B] Graph
of Top2α activity based on densitometry of
low molecular weight decatenated and
linear kDNA bands. The graph shows the
relative percent enzyme activity in DOX or
GPX-containing reactions compared to
uninhibited reactions. The IC50 results
(inset) are the average of 4 experiments ±
standard error of the mean (± SEM).

46
products, the concentration of DOX and GPX compounds required to inhibit 50% (IC50)
of Top2α activity was estimated (Figure 2B). The IC50 of GPX-150 (1.15 µM) was
approximately 3-4 fold higher than the IC50 for GPX-160 (0.32 µM) and DOX (0.23 µM).
This finding may help explain the generally less potent in vitro cytotoxicity profile
exhibited by GPX-150 as ascribed below. The findings also suggest that the alterations to
DOX structure that reduce the GPX-150 inhibition of Top2α (loss of C-13 carbonyl,
iminiquinone ring) are largely overcome by changing the 3’ amine group on the sugar
moiety to the bulkier pyrrolino-group found in GPX-160, which appears to promote the
formation of the ternary complex of drug-DNA-Top2α important for topoisomerase
inhibition25. Our study shows the effect of 3’ substituents on the ability to stimulate Top2mediated DNA cleavage and is consistent with earlier studies29.
2.2

Cytotoxicity studies
The antiproliferative activities of DOX, GPX-150, and GPX-160 against a panel of

seven STS, two breast carcinoma cell lines, and two normal cell lines were measured using
a resazurin reduction assay30. Representative graphs of cytotoxicity profiles against DOXsensitive and DOX-resistant human uterine sarcoma lines are shown in Figure 3. DOX
showed an IC50 of 0.56 µM for the drug sensitive MES-SA cell line, while the IC50
increased about 25-fold to 13.3 µM for the drug-resistant MES-SA/MX2 line. This result
is consistent with literature reports that attribute DOX resistance to the upregulation of Pglycoprotein (P-gp) efflux protein expression27. In contrast, GPX-160 showed similar IC50
values (0.76 µM and 0.73µM) against both the DOX sensitive and resistant MES-SA lines
(Table 1).
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Figure 2.3. In vitro drug sensitivity profiles for human uterine sarcoma cell
lines, MES-SA (DOX sensitive, left) and MES-SA/MX2 (DOX resistant, right).
The graphs represent the average of 3-5 independent experiments ±SEM.
Our results suggest that replacement of the 3’ amino group of the sugar with a 3’
pyrrolino- group reduces the drug susceptibility to P-gp activity. Supporting this
observation, Frezard et al. (2001) reported that modification of anthracyclines with the
electrophilic pyrrolino group decreased P-gp-mediated efflux kinetics and improved
intracellular retention time31. Other investigators have also proposed that the C-3’ position
in the sugar moiety is important not only as a substrate for P-gp mediated efflux, but also
for impacting the sequence specificity and binding affinity of the drug in the minor groove
of DNA25-27.
The results of anticancer drug sensitivity studies are summarized in Table 1. GPX-150
was the least potent analog, with IC50 values in the low micromolar range against sarcoma
and carcinoma cells. These concentrations were generally an order of magnitude (or
greater) than those found for DOX, which fairly consistently yielded sub-micromolar IC50
values. Our in vitro antiproliferative efficacy of DOX showed similar results to previously
reported studies against several STS32 and carcinoma cell lines33. With the exception of the
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Table 2.1. Summary of drug activity against human sarcoma and carcinoma
cell lines.
IC50 (μM)*
GPX-150

Cell Line

Tumor Type

HT1080
HT1080-luc2
RDCCL136
SW-982
SW-872

Fibrosarcoma
Fibrosarcoma
Rhabdomyosarcoma
Synovial sarcoma
Liposarcoma

0.48 ± 0.21
0.73 ± 0.26
0.43 ± 0.05
4.28 ± 1.46
0.35 ± 0.89

47.6 ± 15.5
3.32 ± 0.59
11.9 ± 3.99
0.80 ± 0.68
7.38 ± 0.45

3.87 ± 0.50
3.51 ± 1.79
0.44 ± 0.13
0.45 ± 0.14
0.57 ± 0.23

MES-SA (DOXS)

Uterine sarcoma

0.56 ± 0.08

10.6 ± 1.00

0.76 ± 0.16

MES-SA/MX2 (DOXR)

Uterine sarcoma

13.3 ± 1.68

17.8 ± 0.52

0.73 ± 0.04

DOX

GPX-160

Breast carcinoma
0.34 ± 0.04 43.9 ± 9.13 0.44 ± 0.21
MCF-7
MDA-MB-231
Breast carcinoma
0.20 ± 0.01 7.14 ± 1.92 0.17 ± 0.01
*Expressed values are the mean (±SEM) of 3-5 independent experimental determinations.

HT1080 fibrosacroma cell line, GPX-160 showed sub-micromolar IC50 values against
cancer cells. Overall, the GPX-160 cytotoxicity profile was more similar to DOX than to
GPX-150.
The cytotoxicity of DOX, GPX-150, and GPX-160 against two normal human cell
lines, human adult dermal fibroblasts (HADF) and human umbilical vein endothelial cells
(HUVEC-2) were also examined and are summarized in Table 2. Our IC50 values of DOX
against fibroblast and endothelial cells correlate to previously reported studies34. Nonproliferative HADF cells were insensitive to the compounds, with IC50 values of
approximately 300 µM for all three drugs. Non-proliferative HUVEC-2 cells were also
Table 2.2 Summary of drug activity against normal human cell lines.

HADF
HUVEC-2

Cell Type

Cell Status

Dermal
fibroblast

Proliferative
Non-proliferative

Umbilical
Proliferative
endothelium Non-proliferative

IC50 (μM)*
DOX
57.5 ± 14.8
342 ± 123

GPX-150
19.2 ± 1.1
322 ± 72.4

GPX-160
5.6 ± 1.2
299 ± 68.0

5.4 ± 2.1
41.9 ± 8.1

34.1 ± 10.4
110 ± 22.6

14.0 ± 2.0
33.9 ± 4.8

*Expressed values are the mean (±SEM) of 3-5 independent experimental determinations.
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resistant to compounds, although the IC50 values were at least 3-fold or lower than those
seen for HADF cells. As expected, both normal cell lines showed increased sensitivity to
all three drugs when they were in a proliferative state, with the IC50 values reduced to the
5-50 µM range. These IC50 values were still generally 10- to 100-fold higher than those
found for cancer cells. The results suggest that GPX-150 and GPX-160 will show
selectivity for cancer cells that is similar to that seen with DOX.
2.3

Inhibition of human sarcoma xenografts
The efficacy of GPX-150 and GPX-160 treatment on tumor growth was studied using

luciferase-expressing human fibrosarcoma xenografts established in female (Foxn1nu)
nude mice. Tumor growth was monitored using bioluminescent imaging (BLI) and caliper
measurements in PBS, DOX, GPX-150, and GPX-160 treated mice (Figure 4). On day 20
post-tumor engraftment, mice were imaged for the final time, and the tumor volume and
weights were measured following euthanasia. PBS-treated (control) mice showed the
largest tumors, averaging approximately 4100 mm 3 or 3.1 g in weight (Figure 4, panel B
and C). Reflective of their similar in vitro activities against the HT1080-luc2 cells (Table
1), GPX-150 and GPX-160 treatment (2.4 mg/kg) resulted in similar decreases in tumor
volume and weight. On average, treatment with the GPX compounds significantly
decreased tumor volume by 71-76% and tumor weight by 60-67% relative to the PBS
treatment (ρ < 0.0001). In contrast, mice treated with DOX (2.4 mg/kg) showed the most
dramatic inhibition of tumor growth, with a 99% reduction in volume and 96% decrease in
weight. Although this was a highly effective response to DOX treatment, the mice in this
group exhibited the strongest signs of drug toxicity, based on poor activity, hunched
appearance, and a 10% decrease in body weight relative to control animals (data not
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shown). This result is consistent with other reports that have attributed these observations
to the well-known cardiotoxic side effects of DOX35-37.
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Figure 2.4. Effects of DOX, GPX-150, and GPX-160 treatment (2.4
mg/kg) on human HT1080-luc2 fibrosarcoma xenograft tumor growth in
female athymic nude mice (Foxn1nu). [A] Representative BLI of
xenografts at the start (day 5) and end of treatment (day 20). [B] Average
tumor volumes (± SEM) at sacrifice (day 20). [C] Average tumor weights
(± SEM) at sacrifice (day 20). Graphs show the average of data collected
from groups of 4 (PBS) or 5 (DOX, GPX-150, GPX-160) mice, each
bearing 2 tumors. * ρ < 0.0001 when compared to PBS control treated
mice.
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3. Conclusion
The biological activities of DOX and two novel DOX analogs, GPX-150 and GPX160, were characterized and compared. The analogs were designed to decrease potential
cardiotoxic side effects of DOX by eliminating the C-13 carbonyl group and altering the
quinone ring structure to an iminoquinone that produces less RONS formation. In addition,
in the GPX-160 analog the 3’ amino group on the sugar in the GPX-160 analog was
replaced with a pyrroline to improve intracellular retention. Both GPX-150 and GPX-160
were potent inhibitors of human Top2α, although the IC50 value for GPX-150 (1.15 µM)
was 3- to 5-fold higher than seen with either DOX or GPX-160. In in vitro antiproliferation
assays against a panel of sarcoma and carcinoma cells, the IC50 values obtained for GPX160 were generally in the sub-micromolar range and resembled those found for DOX.
GPX-160 was also consistently superior to GPX-150 in antiproliferative activity, probably
due to decreased activity as a substrate for P-gp mediated drug efflux. Support for this
assertion can be seen in the results from the MES-SA (DOXS) and MES-SA/MX2 (DOXR)
cell studies. MES-SA/MX2 cells overexpress P-gp and showed a 20-fold increased
resistance to DOX, but remained susceptible to GPX-160. This suggests that the
incorporation of the bulkier pyrroline in place of the amino group of the sugar was
successful in reducing efflux of the drug through P-gp. Finally, a pilot study using a human
fibrosarcoma xenograft model in nude mice indicates that GPX-150 and GPX-160 are
promising anticancer drugs with the ability to significantly reduce both tumor volume and
weight. This finding is supported by the results of an initial clinical trial for GPX-150
treatment of advanced sarcoma patients that was recently reported by Holstein et al. 24. In
this study, sarcoma patients treated with GPX-150 showed clinically significant
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improvements in disease progression and no demonstrable drug-induced cardiotoxicity,
although the required dose of GPX-150 was four-fold higher than what would be used for
DOX. Future studies will include a more extensive examination of drug efficacy and
delivery schedules in the HT1080-luc2 fibrosarcoma xenograft model. Considering the
overall better antiproliferative profiles seen for GPX-160 in drug-resistant cells, future
work will also include studies of efficacy using in vivo models of drug resistant tumors in
mice.
4.
4.1

Materials and Methods

Materials and Reagents
GPX-150 and GPX-160 were supplied by Gem Pharmaceuticals, LLC (Birmingham,

AL). DOX-HCl was purchased from Advanced ChemBlocks, Inc. (Burlingame, CA). All
compounds were dissolved in 100% anhydrous dimethyl sulfoxide (DMSO) obtained from
Sigma-Aldrich (St. Louis, MO) to 30 mM and stored frozen at -80 °C. Unless otherwise
noted, all media and media constituents were purchased from Thermo Fisher Scientific
(Pittsburgh, PA).
4.2

Topoisomerase IIα Assay
Top2 activities against antitumor agents were evaluated by observing the decatenation

of kinetoplast DNA (kDNA), which consists of highly catenated networks of minicircular
(2.5 kb) and maxicircular DNA (8 kb), using a Topoisomerase II assay kit (TopoGEN Inc.,
Buena Vista, CO). The measurement of decatenation activity is ATP-dependent and results
in individual minicircles of DNA. The assay was performed in a reaction mixture (20 μl)
containing 232 ng of kDNA, 2 units of human Top2, varying concentrations of test
compounds, and assay buffer consisting of 50 mM Tris-HCl (pH 8), 155 mM NaCl, 10 mM
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MgCl2, 0.5 mM dithiothreitol (DTT), 30 μg/ml boving serum albumin (BSA), and 2 mM
ATP. DOX and DOX analogs were pre-incubated with kDNA for 6 hours at 37 °C prior to
initiating the reaction by addition of enzyme. After 60 min incubation at 37 °C, the reaction
was terminated with stop buffer to achieve a final concentration of 1% Sarkosyl, 0.025%
bromophenol blue, and 5% glycerol. The reaction products were separated by
electrophoresis on a 1% agarose gel submerged in 1x TAE buffer at 12V/cm, followed by
ethidium bromide staining (0.5 μg/ml in 1x TAE). Gels were visualized and imaged using
ultraviolet illumination on a FluorChem E gel imager (ProteinSimple, San Jose, CA).
4.3

Cell Lines and Cell Culture
Six human soft tissue sarcoma (STS) cell lines (HT1080, RDCCL, SW-982, SW-872,

MES-SA, MES-SA/MX2) were purchased from American Type Culture Collection
(ATCC, Manassas, VA). The bioluminescent HT1080-luc2 fibrosarcoma line was
purchased from Perkin Elmer (Waltham, MA). Normal human umbilical vein endothelial
cells (HUVEC-2) and human adult dermal fibroblast (HADF) were purchased from
Thermo Fisher Scientific. MCF-7 and MDA-MB-231 breast carcinoma were the kind gift
of Dr. Cheryl Jorcyk (Boise State University). All cells were cultured at 37 °C with 5%
CO2 in a humidified atmosphere. RDCCL136, SW-982, SW-872, MES-SA, MESSA/MX2, MDA-MB-231 and MDF-7 cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/v)
penicillin/streptomycin (pen/strep). The drug-resistance phenotype of MES-SA/MX2 was
maintained by culturing in the presence of 1 μM DOX until the assay treatment of DOX
and DOX analogs. Huvec-2 and HADF were grown in complete endothelial growth
medium and fibroblast medium, respectively (Sciencell Research Laboratories, Carlsbad,
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CA). HT1080 and HT1080-luc2 were grown in Minimum Essential Medium (MEM),
containing 10% FBS and 1% pen/strep.
4.4

Antiproliferative Assays
In vitro antiproliferative studies were performed using a resazurin reduction assay as

previously described33. Briefly, cells were washed three times with sterile PBS (Thermo
Fisher Scientific, Waltham, MA) and suspended in trypsin-EDTA (Lonza, Walkersville,
MD) for less than 5 min at 37°C. Cells were centrifuged at 200 x g for 5 min and
resuspended in the appropriate media to yield 250,000 – 400,000 cells/mL. Cells were
seeded into sterile 96-well plates (5,000 – 8,000 cells/well) and then incubated overnight
at 37°C in a 5% CO2 humidified atmosphere. The media was then replaced with 200 μl of
fresh media with the appropriate concentration of drug. For cytotoxicity test against MESSA/MX2, 1 µM of DOX pressure was applied during cell culture prior to the drug
treatment. Cells were incubated with drug for 48 h followed by addition of 20 µL of 0.1%
(w/v) resazurin to each well. Fluorescence scans (excitation/emission: 530/590 nm) were
obtained after 4-24 hours using a BioTek Synergy HT Multi-detection microplate reader
(Winooski, VT). Fluorescence data was graphed as the % viability (Equation 1) versus
drug concentration using GraphPad Prism software (La Jolla, CA).
% 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =

drug treated fluorescence−blank fluorescence
Drug−free fluorescence

x 100

𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 (1)

The IC50 values of DOX and DOX analogs were determined using a non-linear fit of the
% viability vs. log [drug].
4.5 In vivo Fibrosarcoma Xenograft Model
The in vivo protocol was modified from Wang et al. (2010). All animal manipulations
and protocols were conducted and approved by the Boise State University Institutional
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Animal Care and Usage Committee #007-AC17-012 (IACUC). Four to five-week-old
female immunodeficient mice (Hsd:Athymic Nude-Foxn1nu) were purchased from Envigo
(Hayward, CA) and housed in the Boise State University vivarium. Animals were
acclimated to the facility for two weeks prior to the beginning of the experiment. To create
the fibrosarcoma xenografts, HT1080-luc2 cells were cultured and harvested as described
as above, resuspended in sterile MEM (1 x 107 cells/mL) and placed on ice until injection.
Mice were injected subcutaneously over both left and right shoulders with 0.1 mL tumor
cells (1 x 106 cells per site). Mice were observed daily for tumor growth and overall health,
and body weights collect three times per week. On day 5 following HT1080-luc2 cell
injection, engrafted tumors were visualized by BLI. For BLI, mice were injected
intraperitoneally (IP) with 0.2 mL sterile D-luciferin solution (15mg/mL in PBS), and the
luciferin allowed to absorb for 10-15 min. The mice were then imaged using a Xenogen
Spectrum IVIS instrument (PerkinElmer, Waltham, MA). Mice were randomly assigned to
treatment groups (4-5 mice/group) consisting of drug (DOX, GPX-150, GPX160) or
vehicle control (PBS). The mice received 100 μl of freshly prepared test compound (2.4
mg/kg) three times per week by intraperitoneal (IP) injection for a total of six treatments
(days 5, 7, 10, 12, 14, 17). Tumor size was measured three times a week with a Vernier
caliper and the tumor volume calculated using the formula for an ellipsoid (Equation 2)38.
4

𝐿

𝑊

𝐻

𝑇𝑢𝑚𝑜𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 = 3 𝜋 ∙ (2) · ( 2 ) ∙ ( 2 )

𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 (2)

To image the luciferase labeled tumors, d-Luciferin potassium salt (PerkinElmer,
Waltham, MA) was dissolved in sterile PBS at 10 mg/ml, and injected intraperitoneally 10
min prior to image acquisition. BLI images were collected twice per week until day 21
(sacrifice). Mice were sacrificed 21-days after tumor cell engraftment due to the excessive
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enlargement of the tumor (> 1.5 cm3). Lungs and primary tumors were excised to determine
metastasis and to measure the volumes and weights, respectively. The excised tumors and
organs were preserved in the 10% formalin tissue fixatives (Sigma-Aldrich, St. Louis, MO)
for further analysis. Prior to tumor injections, euthanasia, and BLI measurements, all the
animals were anesthetized under isoflurane inhalation.
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CHAPTER THREE: ANALYSIS OF NOVEL IMINOQUINONE ANALOGS
REVEALS DISTINCT IN VITRO PHARMACOKINETIC PROFILES
Abstract
Two iminoquinone analogs, GPX-150 and GPX-160, have been explored as
anthracycline replacements to overcome cardiotoxic side effects and drug resistance
profiles commonly encountered with doxorubicin (DOX) therapy. In vitro pharmacokinetic
characteristics were determined to better understand how GPX-150 and GPX-160 compare
to drug parameters displayed by DOX. Drug stability studies in serum containing media
show that both analogs have 3-8 fold longer half-lives than DOX. The apparent
permeability coefficients (Papp) across human epithelial colorectal adenocarcinoma (Caco2) cell monolayers demonstrate that both analogs show increased transepithelial transport
rates in both apical (AP) to basolateral (BL) and BL to AP directions compared DOX. The
results also show that the transepithelial efflux-to-uptake ratio of both GPX-150 and GPX160 are lower than DOX in the BL to AP direction. This suggest the analogs will be less
sensitive to drug efflux and loss into the intestinal lumen. Human liver microsome
cytochrome P450 (CYP450) metabolism of the analogs was examined with and without
CYP450 selective inhibitors. The results showed that CYP2C8 and CYP3A4 were the most
prevalent enzymes involved in modification of GPX-150 and GPX-160. Importantly, both
analogs were insensitive to aldo-keto reductase (AKR) activity responsible for the
conversion of DOX to cardiotoxic doxorubicinol. Mass spectrometry analysis of the liver
microsomal drug products demonstrated metabolism of GPX-150 and GPX-160 occurred
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through dealkylation, demethylation, and deglycosylation routes. Ultimately, the in vitro
pharmacokinetics characterization of GPX-150 and GPX-160 will be useful in promoting
their use as DOX replacements in cancer chemotherapeutic regimens.
1. Introduction
Doxorubicin (DOX, Adriamycin®) is a chemotherapeutic agent used for various forms
of cancer such as breast and ovarian carcinoma, lung and pediatric cancers, lymphoma,
leukemia, multiple myeloma, and soft tissue sarcomas1. The anticancer effects of DOX are
known to be mediated through a number of mechanisms, but primarily by acting as a DNA
intercalating agent that stabilizes the DOX-DNA-topoisomerase II ternary complex2.
Despite the therapeutic successes of DOX, its clinical application is limited due to dosedependent acute and chronic cardiotoxicity that can lead to congestive heart failure
(CHF)3,4. In addition, innate or acquired DOX resistance by cancer cells is a commonly
encountered cause of treatment failure and necessitates the development of new
chemotherapeutics5,6.
Numerous mechanisms of DOX cardiotoxicity have been studied and proposed7. One
of the major mechanisms responsible for DOX cardiotoxicity is the aldo-keto reductase
(AKR) mediated reduction of the C-13 carbonyl group to the corresponding alcohol
metabolite, doxorubicinol (DOXol)8,9. DOXol accumulates in the cardiomyocyte and is up
to ten-fold more potent than DOX in stimulating cardiotoxicity10. DOXol inhibits the Na+K+ pump of the cardiomyocyte sarcolemma, interrupting ion signaling involved in cardiac
contraction and leading to CHF11.
To prevent the formation of DOXol and overcome the undesirable side effects of DOX,
the iminoquinone analogs GPX-150 and GPX-160 were developed (Figure 1)12. GPX-150
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contains two structural changes from DOX: the elimination of the C-13 carbonyl group to
prevent formation of DOXol, and the replacement of a carbonyl in the quinone ring to

Figure 3.1.

The structures of doxorubicin, GPX-150, and GPX-160.

create an iminoquinone with reduced capacity to generate reactive oxygen and nitrogen
species (RONS)11–15. GPX-160 retains the basic structure of GPX-150, but replaces the
primary amine on the sugar with a pyrrolino group that is proposed to reduce its
susceptibility to P-glycoprotein (P-gp) mediated efflux [PMID: 21075206]. GPX-150 and
GPX-160 display in vitro cytotoxicity and efficacy profiles that are comparable to DOX
(see chapter 2).
The purpose of this study is to better understand in vitro pharmacokinetics of GPX-150
and GPX-160 relative to the parent DOX compound. The analogs were evaluated for drug
stability, fluorescence profiles, in vitro intestinal permeability, and identification of the
CYP450 isozymes involved in their metabolism. Using liquid chromatography tandem
mass spectrometry, metabolic breakdown products of DOX and it analogs were identified
and compared. Ultimately, these studies illuminate aspects of basic drug characteristics
that demonstrate several superior features for the analogs over DOX, and serve as useful
background information for future drug development and predicting the behavior of these
compounds in clinical trials. ADD Mitchell’s Intro Sentence HERE.
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2. Materials and methods
2.1 Drug stability studies
The stability of DOX, GPX-150, and GPX-160 in a biological environment was
examined by diluting samples of drug stock solutions (10 mM in DMSO) to a final
concentration of 250 µM in Dulbecco’s Minimal Essential Medium (DMEM) containing
10% fetal bovine serum (FBS) (v/v) and 1% pen/strep (100 U/ml penicillin and 100 μg/ml
streptomycin). Samples were vortexed briefly to mix, filtered through 0.22 µm PTFE
syringe filters, and analyzed by high-performance liquid chromatography (HPLC).
Analysis was performed on a 50 mm x 4.6 mm Hypersil GOLD phenyl column (5 μm pore
size) using an Agilent 1100 series HPLC equipped with a diode array detector. Mobile
phases A and B consisted of 52 mM Tris base (pH 7.2) and 99.9% HPLC-grade acetonitrile,
respectively. Gradients were conducted with a flow rate of 1.0 ml/min for 15 min with the
following linear program: t = 0 min (70%; A, 30%; B), t = 10 min (30%; A, 70%; B),
t=12min (30%; A, 70%; B), t=12.1min (70%; A, 30%; B), and t = 15 min (70%; A, 30%;
B). Samples (20 µL) were injected every 15 min until near complete decomposition was
observed. The retention times for DOX, GPX-150, and GPX-160 were 4.3, 3.8, and 4.9
minutes, respectively. Drug decomposition was observed as decreases in integrated peak
areas. Drug half-lives were calculated from plots of integrated peak area vs. time, and fit
using one-phase decay based on first-order kinetics.
2.2 Drug transport studies
To develop epithelial cell monolayers, 1.5 x 105 Caco-2 cells (ATCC, Manassas, VA)
were seeded in 24-well plates containing Transwell® permeable polycarbonate inserts (6.5
mm diameter; Corning, Tewksbury, MA) and cultured in -MEM (Thermo Fisher
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Scientific, Waltham, MA) supplemented with 10% FBS and 1% pen/strep. The media was
replenished every 2 day. The plates were incubated at 37 °C in a 5% CO2 humidified
atmosphere for 21 days until the cell monolayers were fully developed. In the polarized
cell monolayers, the apical and basolateral sides face the upper and lower transwell
chamber, respectively. The integrity of the polarized monolayers was evaluated by
transepithelial electrical resistance (TEER) measurements using an EVOM2 epithelial
voltohmmeter (World Precision Instruments Inc., Sarasota, FL). Transport studies were
initiated when the TEER values of each well surpassed 300 Ω•cm2. TEER values of 555 ±
32 Ω•cm2 at 37 °C, and low Lucifer yellow (LY) permeability rates (< 0.5x10-5 cm/s) indicate good
integrity of the Caco-2 monolayer.

For transport experiments, both upper and lower Transwell® chambers were washed
three times with pre-warmed 1x Hank’s balanced salt solution (HBSS, HyClone
Labratories. Inc., Logan, UT). After washing, the plates were incubated in fresh HBSS for
30 min at 37 °C. For the apical to basolateral (AP-BL) uptake experiment, 450 μl of test
solutions (25 µM drug) was added to the AP side, and 1600 μl of pre-warmed HBSS was
added to the BL well chamber. LY (25 µM) served as a control for non-specific paracellular
transport. At intervals of 30, 60, 90, 120, 150 min later by removing 200 μl from the BL
chamber. This volume was replaced with an equivalent volume of fresh HBSS. The plates
were incubated in an orbital shaker at 37 °C at 50 rpm between the time intervals.
To evaluate the BL-AP drug efflux of the test compounds, 1600 μl of the test solutions
(containing 50 µM drug in HBSS) was added to the BL chamber, while 450 μl of HBSS
without test compound was added to AP side. A 150-μl aliquot was collected from the AP
side at time intervals of 30, 60, 90, 120, and 150 min, and was replaced with an equivalent
volume of HBSS. Sample concentrations were assessed using a BioTek fluorescence
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microplate reader with the following settings: DOX (ex. 490/em. 590 nm); GPX-150 (ex.
560nm/ em. 630nm); and GPX-160 (ex. 560 nm/ em. 630 nm). The amount of transported
durg was determined from standard curves of drug concentration versus fluorescence. The
apparent permeability coefficients (Papp, cm/s) for the test compounds were determined
according to the following equation18:
Papp = (dCr/dt) x Vr / (A x C0)

Equation (1)

where dCr/dt is the change of concentration of test compounds in the receiver chamber
(μg/s), Vr is the volume of receiver chamber, A is the area of the inserts (0.33 cm2), and Co
is the initial concentration of drugs (50 μM). The efflux ratio was determined as:
Efflux ratio (ER) = Papp (BL-AP) /Papp (AP-BL)

Equation (2)

2.3 Microsomal metabolism of DOX and DOX analogs
The initial rates of DOX and DOX analog metabolism by human liver microsomes
(HLMs) were determined based on the method of Quintieri et al.19 that follows the change
in fluorescence of the reaction as NADPH is oxidized to NADP+. The 2-ml reaction
mixture consisted of 0.1 M potassium phosphate (pH 7.4), 0.15 mM NADPH, and 50 μM
DOX or DOX analog. The reaction was preincubated for 3-minute at 37°C, and initiated
with the addition of 0.1 mg/ml HLMs (50 donor pool, Sekisui XenoTech LLC, Kansas
City, KS) containing approximately 50 nmol CYP450 protein. Controls consisted of
reactions conducted without microsomes, without NADPH, or without test drug. All
reactions were tested in triplicate using a Cary Eclipse spectrofluorometer (Varian, Palo
Alto, CA) and scanned (ex. 340 nm/em. 460 nm) for 1 hour at 37 °C.
To begin to identify the microsomal enzymes responsible for GPX-150 and GPX-160
metabolism, fluorometric HLM assays (above) were conducted in the presence and absence
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of aldo-keto reductase (AKR), alcohol dehydrogenase (ADH), or CYP450 isozyme
specific enzyme inhibitors selected based on literature reports11,15-17. All inhibitors were
obtained from Sigma-Aldrich (St. Louis, MO). ADH- and AKR-specific inhibition was
measured using 50 µM 4-methylpyrazole (ADH) or 50 µM quercitrin (AKR), or. For CYP
specific inhibition, the following selective inhibitors were used: 10 µM xanthotoxin
(CYP2A6), 60 µM quercetin (CYP2C8), 30 μM sulfaphenazole (CYP2C9), 10 μM
quinidine (CYP2D6), 5 μM ketoconazole (CYP3A4).
2.4 Identification of DOX and DOX analog metabolic products by mass spectrometry
HLM metabolites of DOX, GPX-150, and GPX-160 were identified using HPLC and
mass spectrometry (HPLC-MS). HLMs assays were performed as described above, but
modified to contain 50 µM test drug and scaled to a final volume of 400 µl. Controls
consisted of reactions with denatured microsomes (45 °C / 30 min), reactions without
NADPH, or reactions without test drug. Reactions were terminated after 60 minutes at 37
°C with the addition of 400 μl ice-cold acetonitrile. Precipitates were removed by
centrifugation at 10,000 x g for 30 min. Sample aliquots (20 µl) were injected onto a
Hypersil GOLD phenyl analytical column (50 mm x 4.6 mm) using an Agilent 1100 HPLC
coupled to a HCTultra ETDII electrospray ionization mass spectrometer (Bruker Daltonik
GmbH, Bremen, Germany). Chromatographic separations were achieved using a 1 mL/min
flow rate of 79 mM ammonium formate (Solvent A, pH 4.2) and 100% acetonitrile (solvent
B) as mobile phases. A gradient elution program: t = 0 min (70% A, 30% B), t = 10 min
(30% A, 70% B), and t = 12.1 min (70% A, 30% B) was used. Doxorubicin elution was
detected at 495 nm. GPX-150 and GPX-160 elution were detected at 560 nm. The retention
times of DOX, GPX-150, and GPX-160 were 4.1, 4.1, and 5.2 minutes, respectively.

68
The mass spectrometer was operated in positive ion mode using a 6 kV of source
voltage. Data were collected under full scan mode from 100 – 800 m/z and analyzed using
an Esquire 6000 software program. Nine m/z values (544.2, 529.2, 581.2, 382, 364, 346,
321, 200, and 147 m/z) were used to conduct an enhanced quadratic calibration within the
expected mass range of fragments of the compounds.
3. Results
60

3.1 Drug stability of DOX, GPX-150, and GPX-160

were determined to compare the stability of the analogs to
DOX. As seen in Figure 2, the average half-life of DOX
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Figure 3.2. Drug
degradation of DOX, GPX150, and GPX-160. Drug
half-lives were determined
based on one phase decay
analysis of integrated peak
areas from HPLC.

epithelia
The in vitro transport rates of DOX, GPX-150, and GPX-160 were evaluated using
mature, polarized Caco-2 cell monolayers to simulate the human intestinal environment.
In the assay, monolayer integrity was indicated by examining the transport of hydrophilic
Lucifer yellow (LY) dye, which is poorly transported across the intact epithelial cell
membrane bilayer20. The apparent permeability coefficients (Papp) for DOX, GPX-150, and
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GPX-160 were evaluated as a preliminary investigation into transport capability across the
intestinal epithelia. As seen in Figure 3 and summarized in Table 1, measurements of basal
to apical (BL-AP) permeability coefficients indicate that GPX-150 and GPX-160 have
significantly greater efflux (p≤ 0.05) across the monolayer relative to DOX. Similarly,
apical to basal (AP-BL) permeability coefficients that were significantly higher in GPX150 and GPX-160 (p ≤ 0.05 and p ≤ 0.01) compared to DOX. The results show that GPX150 and GPX-160 are much more permeable across the monolayer in either direction than
DOX. When the ratio of efflux-to-uptake is considered, DOX exhibits a strong preference
for BL-AP efflux with a Papp ratio of 2.5 (Figure 3). In contrast, GPX-150 and GPX-160
exhibited ratios near 1, which indicates no strong preference for direction of transport.
A

B

C

Figure 3.3. Apparent permeability rates (Papp, cm/s) of DOX, GPX-150,
and GPX-160 transport in basal to apical (A) and apical to basal (B)
directions. The figures show the average of three independent experiments (±
SEM). * and ** represent p≤ 0.05 and p≤ 0.01, respectively. The efflux ratio
(C) explains the ratio of average permeability rates of efflux (BL-AP) to
uptake (AP-BL) across the epithelial monolayer.
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Table 3.1.
Summary of apparent permeability rates (Papp) of
bidirectional drug transport.
Ave. Papp (x10-6 cm/s)*
LY**
DOX
GPX-150
4.0 ± 1.4
20.0 ± 5.0
42.0 ± 5.8
BL to AP
4.8 ± 2.4
8.3 ± 4.0
32.4 ± 12.8
AP to BL
0.83
2.46
1.30
Efflux ratio
* Average of 3 experiments ±SEM. ** Lucifer yellow control

GPX-160
50.1 ± 10.5
43.3 ± 10.0
1.16

3.3 Microsomal metabolism of DOX and DOX analogs
The preliminary data on the microsomal metabolism of DOX, GPX-150, and GPX-160
was determined by examining the loss in fluorescence (ex. 340 nm / em. 460 nm) of a
reaction that accompanies the corresponding oxidation of NADPH to NADP+. As seen in
Figure 4 (upper left panel), the microsomal oxidation rate of NADPH when GPX-150 or
GPX-160 were substrates was approximately half that seen for DOX.
The application of selective inhibitors to the HLM assays provided initial information
on the enzyme activities important for DOX, GPX-150, and GPX-160 metabolism. The
results of the analysis show that DOX metabolism was inhibited by 40-85% when
inhibitors of five CYP450 isoforms (2A6, 2C8, 2C9, 2D6, 3A4), alcohol dehydrogenase
(ADH) or aldo-keto reductase (AKR) were incorporated into the reactions (Figure 4). Of
these results, quercetin (CYP2C8-selective, 85% inhibition), ketoconazole (CYP3A4selective, 70% inhibition) and quercitrin (AKR-selective, 81% inhibition) showed the
greatest effects, indicating that CYP2C8, CYP3A4, and AKR were most important
enzymes in DOX microsomal metabolism.
In contrast to DOX, GPX-150 and GPX-160 metabolism was relatively insensitive (≤
20% inhibition) to xanthotoxin (CYP2A6-selective), sulphenazole (CYP2C9-selective),
quinidine (CYP2D6-selective), 4-methylpyrazole (ALDH-selective), or quercitrin (AKR-
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selective). The most striking inhibition of GPX-150 and GPX-160 metabolism occurred
only when reactions contained quercetin (CYP2C8-selective, ~ 60% inhibition) and
ketoconazole (CYP3A4-selective inhibitor, ~ 50-70% inhibition.). As expected based on
the loss of the C-13 carbonyl group and poor quercitrin inhibition (AKR-selective), aldoketo reductase activity was not an important factor in GPX-150 or GPX-160 metabolism.

Figure 3.4
HLM metabolism of DOX, GPX-150, and GPX-160. NADPH oxidation
rates were > 2-fold higher for DOX than for the DOX analogs (upper left panel). The
remaining panels show percent metabolic activity (compared to uninhibited
reactions) when selective cytochrome P450, ADH, or AKR inhibitors were
incorporated into the reactions. The selective inhibitors were xanthotoxin (CYP2A6),
quercetin (CYP2C8), sulfaphenazole (CYP2C9), ketoconazole (CYP3A4), quinidine
(CYP2D6), 4-methylpyrazole (ADH), and quercitrin (AKR). *represents p ≤ 0.0001 in
comparison to DOX.
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3.4 Identification of DOX and DOX analog metabolic products
The products of HLM metabolism of DOX, GPX-150, and GPX-160 were analyzed by
reverse phase HPLC-tandem mass spectrometry (Figure 5). The primary DOX peak eluted
at 4.1 minutes. NADPH in the reactions eluted at 1.9 minutes (data not shown) without
overlapping
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spectra and a schematic for the metabolic
decomposition of GPX-150 can be found
in Appendix B.
GPX-160 and its metabolites (M)
showed retention times of 5.2 and 4.7
minutes, respectively (Figure 5C). The

Figure 3.5. HPLC elution profiles for
HLM reactions containing (A) DOX, (B)
GPX-150, and (C) GPX-160. The spectra
were collected at the λmax for the
respective compounds: DOX (495 nm),
GPX-150 and GPX-160 (560 nm). The
retention times for DOX, GPX-150, and
GPX-160 were 4.1, 4.1, and 5.2 minutes,
respectively. Metabolites (M) were
eluted at 2.5, 2.8, and 4.7 minutes.
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Figure 3.6. Mass spectra of GPX-160 [M+H]+ and its HLM metabolites. F1
denotes a GPX-160 fragment with a characteristic loss of the sugar moiety. The
major metabolites (M1-M5) of GPX-160 eluted at 4.6 - 4.7 minutes from the HPLC
and correspond to the predicted 4-O-demethylation (M1), 5’-demethylation (M2),
dealkylation (M3), hydroxyaglycone (M4) and 7-deoxyaglycone (M5) products.
mass spectra for GPX-160 and its metabolites can be seen in Figure 6. The identity of the
metabolic breakdown products of GPX-160 was assigned using the mass spectra
fragmentation pattern (Figure 6), and predictions of how the compound would be expected
to be metabolized based on literature reports of the mass spectra of CYP450
decompositions of DOX19.
A summary of the compounds identified in the mass spectra of HLM metabolized
DOX, GPX-150 and GPX-160 is found in Table 2. DOX has an observed characteristic
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[M+H]+ peak at 544.17 m/z and a minor peak at 397.1 (F1) that agrees with the predicted
mass of a deglycosylated fragment (Appendix B). Cardiotoxic DOXol, the AKR metabolite
of DOX, appears in the spectra as a peak at 546.75 m/z, close to its predicted 546.19 m/z
peak. Fragments corresponding to demethylation, dealkylation, and deglyosidation
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Table 3.2.
Identities of the m/z peaks in the mass spectra of HLM metabolized
(A) DOX, (B) GPX-150, and (C) GPX-160.
(A)
Peaks
1
2
3
4
5
6
7
8
9
10

Compounds
/reaction
Doxorubicinol
Doxorubicin
Dealkylation
Doxorubicinone
7-deoxydoxorubicinol
7-deoxydoxorubicinone
F1
Demethylation
F2
F3

Measured
m/z
546.7500
544.1644
486.2882
415.1250
401.1587
399.1886
397.0806
387.0625
379.1376
321.0823

Theoretical
m/z
546.1897
544.1741
486.1686
415.0951
401.1158
399.1002
397.0923
387.1002
379.1182
321.0763

Error
(ppm)
1025.8
17.8
246.0
72.0
107.0
221.5
29.5
97.4
51.2
18.7

Retention time
(min)
2.5
4.1
2.4
2.6
2.5
2.5
4.1
2.5
2.4
4.1

(B)
Peaks
1
2
3
4
5
6
7

Compounds
/reaction
GPX-150
4-O-demethylation
Dealkylation
F1
Hydroxyaglycone
7-deoxyaglycone
F2 (loss of water)

Measured
m/z
529.1987
515.2496
485.2241
400.1268
400.125
384.0625
382.1305

Theoretical
m/z
529.2108
515.1951
485.1846
400.1318
400.3900
384.1369
382.1576

Error
(ppm)
22.9
105.8
81.4
12.5
661.9
193.7
70.9

Retention time
(min)
4.1
2.8
2.8
4.1
2.8
2.8
4.1

(C)
Peaks
1
2
3
4
5
6
7

Compounds
/reaction
GPX-160
4-O-demethylation
5'-demethylation
Dealkylation
Hydroxyaglycone
F1
7-deoxyaglycone

Measured
m/z
581.2654
567.2658
553.2239
537.1425
400.2021
400.1167
384.1250

Theoretical
m/z
581.2499
567.2343
553.2186
537.2237
400.3900
400.1318
384.1369

Error
(ppm)
26.7
55.5
9.6
151.1
469.3
37.7
31.0

Retention time
(min)
5.2
4.7
4.7
4.7
4.6
5.2
4.6

reactions of DOX, particularly those catalyzed by CYP2C8 and CP3A4 were observed
(Table 2A).
The [M+H]+ fragment of GPX-150 was found at 529.2 m/z and its expected CYP2C8
and CP3A4 induced metabolites were observed as a series of 384 – 515 m/z peaks. A GPX-
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160 m/z value was found at 581.26, as well as its proposed demethylated (M1, M2),
dealkylated (M3) and deglycosylated (M4, M5) products between 384 - 567 m/z. A
schematic of the proposed metabolic routes of GPX-160 is presented in Figure 7.

Figure 3.7.

Schematic of proposed GPX-160 metabolites by CYP2C8 and
CYP3A4.

4. Discussion
This pharmacokinetic study was conducted to describe the in vitro stability, transport
and metabolism of novel iminoquinone analogs of DOX in order to forecast in vivo drug
characteristics of the compounds when they are used as anticancer agents.
Good drug stability can facilitate improved drug retention and distribution of potential
candidates for cancer treatment21,22. To evaluate the drug degradation rates, we tested
morphologically modified DOX derivatives that replaced the quinone structure with an
iminoquinone to decrease the potential to produce reactive oxygen species associated with
acute cardiotoxicity. The iminoquinone GPX-150 clearly shows an 8-fold increase in drug
stability relative to DOX.
The removal of the C-13 carbonyl from GPX-150 and GPX-160 could increase the
hydrophobicity of the compounds, which could result in increased lipophilicity longer
blood circulation time and higher accumulation in tumors23. GPX-160 showed a 3-fold
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increase in stability relative to DOX, but was less stable than GPX-150. Increased stability
in our assay is potentially due to the less reactive nature of the iminoquinone found in GPX150 and GPX-160. Compared to GPX-150, the reduced stability of GPX-160 may be due
to the positively charged 2-pyrrolino moiety, which is a stronger electrophile than the
primary amine of GPX-150. Potentially, this could lead to GPX-160 non-specifically
reacting with proteins and other biological constituents in the media.
This study also evaluated the bidirectional transcellular transport pathway of DOX,
GPX-150, and GPX-160. The lack of a C-13 carbonyl makes both GPX-150 and GPX-160
more hydrophobic than DOX. This potentially explains the increased transport rate of these
compounds in both the AP to BL and BL to AP directions. Numerous studies have defined
the permeability coefficient less than 1x10-6 cm/s exhibits poor (0-20%), between 1x10-6
cm/s and 10x10-6 cm/s shows moderate (20-70%), and greater than 10x10-6 cm/s displays
substantial absorption (100%)24. Since GPX-150 and GPX-160 show transport rates of 3050 x10-6 cm/s, these compounds would be classified as substantially absorbed. In contrast,
DOX represents a moderately observed compound. Increased transport rates suggest that
GPX-150 and GPX-160 could potentially be delivered orally to treat cancer. However,
further investigation of oral bioavailability such as in vivo studies are necessary to fully
estimate the potential for these compounds to be useful by oral administration.
Furthermore, ratio of efflux to absorption of the anticancer drugs were determined from
ratio between the Papp of BL to AP and AP to BL (Figure 3). DOX shows almost 2.5-fold
higher in BL to AP than AP to BL pathway indicating a high ER (Table 2), which yields
lower cellular uptake of DOX in the intestinal environment as a safety mechanism to
protect the body from xenotoxins25. In contrast, GPX-150 and GPX-160 show ER that are

78
evenly balanced between BL to AP and AP to BL (ER near 1).
The metabolism of DOX, GPX-150, and GPX-160 was initially established using a
NADPH-mediated reaction with HLMs. Further, the CYP450 isozymes responsible for the
drug metabolism was explored using selective CYP inhibitors identified from reported
studies of DOX metabolism60-62. The faster oxidation rate of NADPH to NADP+ in DOX
metabolism is due to the presence of the C-13 carbonyl group that is the substrates for
carbonyl reductase (CR), which is a member of the aldo-keto reducatase (AKR) family, is
a major AKR enzyme that reduces DOX to DOXol in the cardiomyocyte26. DOXol is very
potent in inducing chronic progressive cardiotoxicity and eventually causes CHF27.
Without the presence of C-13 carbonyl in side chain, the oxidation of NADPH in reactions
containing GPX-150 and GPX-160 diminishes as the main active site of CR disappears.
The importance of CR interaction with quinone ring of DOX has also been explained by
enzymatic and computational studies28.
CYP3A4 participates in approximately 50% of CYP450 of the drugs oxidative
metabolism examined up to date30. In adults, 29% of the liver CYP450 enzyme expression
is CYP3A431, while this value rises to 50% in the small intestine32. It is the most abundant
of all of the human CYP isoforms, and is localized in the GI tract, kidney, and liver where
it is particularly relevant to drug elimination33. The results of our studies show that
CYP2C8 and CYP3A4 are the most significant CYP450 isozymes responsible for the
biotransformation of DOX, GPX-150, and GPX-160. The CYP3A4 metabolism of these
compounds is consistent with the reported literature39-41. Interestingly, CYP3A4-mediated
metabolism is also required to transform the pro-drug MMDX (PNU-152243) into the
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active DOX derivative, a compound which was explored in phase I and II clinical trials as
an anticancer agent29.
Our results also showed that CYP2C8 is involved in DOX, GPX-150, and GPX-160
metabolism which is consistent with a literature34. Other studies have shown that CYP2C8
is responsible for the metabolism of numerous drugs including tetracyclic compounds35,36.
CYP2C8 is regulated by the expression of the pregnane X receptor (PXR), which
stimulates expression of P-gp that increase drug resistance of human lung carcinoma37.
Defining the pharmacologic and toxicologic profiles of xenobiotics is an important
prelude to clinical trials. HPLC-MS-MS analysis was used to separate and identify the
parent compounds and their biotransformation products. Based on the major roles of
CYP2C8 and CYP3A4 in GPX-160 metabolism, a proposed schematic of metabolites is
shown in Figure 9. The m/z value of the GPX-160 parent ion was 581.26. CYP2C840 and
CYP3A441 deglycosidation products of GPX-150 and GPX-160 by hydrolytic or reductive
cleavage of the sugar moiety generated the same aglycones with peaks at 400.39 and
384.14 m/z, respectively. Furthermore, CYP3A4-specific dealkylation of GPX-160 would
be predicted to yield a fragment with an m/z value of 537.143, which is supported by the
mass spectra (Figure 6). The remaining demethylation or deglycosidation products seen in
mass spectra could be formed by the action of either CYP2C8 or CYP3A4.
Similar to GPX-160, the aglycone metabolites of GPX-150 were assumed to be
produced by both CYP2C8 and CYP3A4 due to their roles in deglycosidation reactions. In
GPX-150, this corresponds to metabolites peaks with m/z values at 400.39 and 384.14,
respectively (Appendix B). These represent aglycones formed by hydrolytic or reductive
mechanisms. Furthermore, the peaks at m/z of 515.52 and 485.18 suggest demethylation44
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and dealkylation reactions by CYP3A443. The peak at 382.1 m/z is in agreement with the
cleavage of the sugar residue from GPX-150 with subsequent loss of a water molecule.
In the mass spectra of DOX (Appendix B), the main peak occurs with a m/z of 544.16.
Notable peaks with m/z values of 397.1 and 379.1 can be explained by the protonation of
DOX at C-7, loss of the sugar residue, and subsequent collision induced loss of water38,39.
The peak at 321 m/z is consistent with the loss of both the sugar moiety and the alkyl side
chain at C-919. The peaks at m/z 415.2 and 399.2 represent glycosidic cleavages yielding
hydrolytic (doxorubicinone) and reductive (7-deoxydoxorubicinone) aglycones. These are
predominantly formed by CYP2C840 and CYP3A441. Further reduction of the C-13
carbonyl by carbonyl reductase result in 7-deoxydoxorubicinone that corresponds to the
peak at 401.12 m/z. Doxorubicinone can also be reduced by carbonyl reductase to yield
doxorubicinolone42. The peaks at 486.7 and 387.1 m/z correspond to CYP3A4-mediated
dealkylation of the side chain and demethylation of 7-deoxydoxorubicinone,
respectively43.
As with DOX, metabolites of GPX-150 and GPX-160 may show unique toxicities.
However, these are not yet identified. Potentially co-administration of potent inhibitors of
CYP2C8, such as quercetin or glitazones45 and/or inhibitors of CYP3A4, such as azole
antifungals (e.g., ketoconazole and itraconazole)35 and macrolide antibiotics (e.g.,
erythromycin and troleandomycin)46, could preserve the chemotherapeutic efficacy of
GPX-150 and GPX-160. This may be useful when using these analogs to treat certain
human carcinomas including hepatocellular carcinomas that show increased CYP3A4
expression44.
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5. Conclusion
In conclusion, our studies show that GPX-150 and GPX-160 have increased biological
stability and transport rates relative to DOX across Caco-2 monolayers. This suggests they
may have potential for oral delivery. The results of our in vitro studies using CYP450
selective inhibitors demonstrated that the two analogs were predominantly metabolized by
CYP2C8 and CYP3A4. Importantly, the absence of a C-13 carbonyl group abrogated CRmediated formation of toxic alcohol metabolites and significantly decreased microsomal
drug metabolism. This suggests that these analogs could persist longer in vivo than DOX.
Mass spectrometry analysis of the microsomal drug metabolites was consistent with
predictions of CYP2C8- and CYP3A4-mediated metabolism based on known degradation
pathways of DOX. Future animal studies will expand our understanding of the absorption,
distribution, metabolism, and excretion (ADME) of these novel DOX analogs.
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CHAPTER FOUR: CONCLUSION
DOX is among the most prominent and versatile antitumor agents used to treat a variety
of cancer patients. The antineoplastic mechanism of DOX primarily involves intercalating
DNA between base pairs, creating DNA adducts, and inhibiting topoisomerase enzyme
activity during DNA replication. Although effective as an antitumor agent, DOX also
causes a cumulative dose-dependent cardiotoxicity. In an attempt to address this adverse
effect while maintaining efficacy, several synthetic modifications have been made to the
original structure of DOX. GPX-150 and GPX-160, two novel synthetic DOX analogs,
showed inhibitory effects against Top2α, indicating the analogs participate in forming the
Drug-DNA-Top2α ternary complex similar to DOX. In in vitro antiproliferation assays,
both analogs exhibited very promising anticancer activity against an array of cancer cell
lines. In particular, GPX-160 showed similar IC50 values to DOX against human STS while
lacking the structural properties associated with cardiotoxicity. Importantly, GPX-160
appears to overcome DOX resistance due to P-gp mediated drug efflux. Moreover, the
novel analogs both showed promising activity against human fibrosarcoma xenografts in
immune-deficient mice, causing significant reductions in both tumor volume and tumor
weight.
Furthermore, pharmacokinetic studies showed that the analogs had biological stability
that was markedly better than DOX, with drug half-lives in serum containing media that
were 3-8 fold longer than DOX. Transport studies of GPX-150 and GPX-160 across Caco2 monolayers indicate the drugs cross the intestinal epithelial layer much more rapidly than
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DOX, and suggest the drugs may have improved oral bioavailability. The drug metabolic
turnover by HLM CYP450s, ALDH, and AKR show that GPX-150 and GPX-160 are less
metabolically active than DOX. In particular, the lack of C-13 carbonyl in the analogs
appears to prevent their metabolism by AKR, and the formation of the corresponding
cardiotoxic alcohol metabolite, DOXol. CYP2C8 and CYP3A4 were found to be the most
prevalent CYP isozymes for biotransformation of analogs. HPLC-MS-MS analysis
determined dealkylation, demethylation, and deaglycosidation of DOX, GPX-150 and
GPX-160 by CYP2C8 and CYP3A4. Further investigation of these metabolites need to be
done to assess potential toxicities. The project was designed to discover and comprehend
new generation of anthracyclines with improved potency without severe side-effects
compared to that of the parent compound. The novel compounds with structural
modifications of DOX certainly represents the groundbreaking development of anticancer
agents for amplified chemotherapeutic treatment.
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APPENDIX A
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Fluorescence Profiles and Calibration Curves for DOX, GPX-150 and GPX-160
DOX, GPX-150, and GPX-160 spectrofluorometric profiles were determined using a
Varian Cary Eclipse fluorometer to identify the maximum excitation and emission
wavelengths. These values are important for detection of the compounds in transport
studies, and in assessing drug concentration. Fluorometry identified the maximal
excitation/emission wavelengths to be: DOX (ex. 495 nm/em. 593 nm), GPX-150 (ex. 560
nm/em. 630 nm) and GPX-160 (ex. 560 nm/em. 630 nm) as shown in Figure A1. The DOX
excitation profile was similar to the reported literature (Paine, M. F.; Khalighi, M.; Fisher,
J. M.; Shen, D. D.; Kunze, K. L.; Marsh, C. L.; Perkins, J. D.; Thummel, K. E. J.
Pharmacol. Exp. Ther. 1997, 283 (3), 1552). The spectroscopic profiles for both GPX-150
and GPX-160 showed identical wavelengths although GPX-160 contains a pyrrolino group
at C-3’ position in the sugar moiety. This indicates that the absorption and radiation energy
of both of the novel compounds share very similar Stokes fluorescence.
Standard calibration curves were constructed using the optimal excitation and emission
wavelengths and a series of drug concentrations (Figure A2). These calibration curves were
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Figure A1. Spectrofluorometric profiles of DOX, GPX-150, and GPX-160. The
compounds were diluted to 2.5 µg/ml in DMEM. Excitation and emission profiles
are shown in solid and dashed lines, respectively.
later used for drug concentration and transport studies. To construct the calibration curves,
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8 concentrations of test compounds were diluted in HBSS and the fluorescence measured
on a BioTek Synergy MX multiwell plate reader. As can be seen in Figure A2, DOX was
approximately 10-20 fold more fluorescent at its optimal excitation/emission conditions
than GPX-150 or GPX-160. However, the data was linear for all of the compounds in the
0 – 50 µM concentration range, allowing ready detection of low micromolar concentrations
of drug.
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Figure A2. Calibration curves of DOX (495/593 nm), GPX-150, GPX-160
(560/630 nm), and Lucifer yellow (428/536 nm). These calibration curves were used
to examine drug transport across Caco-2 monolayers.
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B1. Doxorubicin

B2. GPX-150

Figure B1.
HLM metabolites of DOX after 30 min at 37°C. The mass spectra
were collected at 4.1 minutes retention time from the HPLC chromatogram for
DOX (M+H+) and the deglycosylated F1 fragment (top panel). The mass spectra
for other metabolites (M1 – M6) was collected at 2.4-2.6 minutes retention time.
See Chapter 3, Table 3 for comprehensive list of metabolites.
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Figure B2.
HLM metabolites of GPX-150 after 30 min at 37°C. The mass
spectra were collected at 2.8 minutes retention time from the HPLC
chromatogram to identify GPX-150 (M+H+) and the deglycosylated (F1) and
deglycosylated/dehydrated (F2) products. The GPX-150 metabolites (M1-M5)
were found at 2.8 minutes retention time. See Chapter 3, Table 3 for
comprehensive list of metabolites.
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B3. Schematic of DOX Metabolism

Figure B3.
Based on LC/MS results, the predicted metabolites of DOX by aldoketo reductase (AKR) and CYP2C8 and CYP3A4 via human liver microsomes
(HLMs).

B4. Schematic of GPX-150 Metabolism

Figure B4.
Based on LC/MS results, the predicted metabolites of GPX-150 by
CYP2C8 and CYP3A4 via human liver microsomes (HLMs).

